Silence Therapeutics (NASDAQ: SLN) recently received a number of ratings updates from brokerages and research firms:
- 10/21/2026 – Silence Therapeutics was downgraded by Chardan Capital from “strong-buy” to “hold”.
- 10/21/2026 – Silence Therapeutics was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $20.00 price target on the stock, down from $75.00.
- 10/19/2026 – Silence Therapeutics was downgraded by Jefferies Financial Group from “buy” to “hold”. They now have a $20.00 price target on the stock.
- 10/19/2026 – Silence Therapeutics was downgraded by William Blair from “outperform” to “hold”.
- 10/15/2026 – Silence Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use small interfering RNA (siRNA) to selectively reduce the production of disease-related proteins. Its approach is designed to intervene at the genetic messenger RNA stage, potentially providing targeted and durable effects for patients with serious diseases.
The company’s proprietary mRNAi GOLD platform supports the design and delivery of siRNA medicines, including compounds intended to target tissues such as the liver.
Read More
- Five stocks we like better than Silence Therapeutics
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
- Off-Price, High-Yield: Why Ross Stores Is Defying the Retail Slump
Receive News & Ratings for Silence Therapeutics PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
